CDR-Life raises USD 76 million in its Series A Financing Round

CDR-Life, a Swiss biotechnology company pioneering a new and differentiated class of highly tumor-specific immune-oncology therapeutics, has completed its Series A financing raising USD 76 million. The round was led by Jeito Capital and RA Capital Management, with participation from Omega Funds.

Homburger advised CDR-Life in the transaction. The Homburger team was led by partner Daniel Häusermann (pictured) and included lead associate Marc Schamaun as well as associates Anna Peter, Daniel Kuhn (all corporate / m&a), associate Philippe Weber (tax) and junior associate Lars Schöni. Homburger partner Dieter Gericke served as independent director of CDR-Life until completion of the financing.